Skip to main content
Novartis Novartis
language-selector-globe
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
United States | English
    • About 
      • Novartis in the UK 
      • Partnerships 
        • Collaborative working 
        • External funding 
        • Patient group partnership 
      • Sponsorships 
      • Diseases 
      • Strategy 
      • People and culture 
      • Who we are 
      01077_144dpi_16by9_PPT_RGB
      About
    • Patients and caregivers 
      • External funding 
      • Patient group partnership 
      Doctor and Patient
      Patients and Caregivers
    • Healthcare professionals 
      • For UK healthcare professionals 
      Healthcare Professional Writing
      Healthcare Professionals
    • ESG 
      • Ethical behaviour 
        • Code of Ethics 
        • Speakup 
      • Ethics, risk and compliance 
      • Access 
      • Environmental sustainability 
      • Global health 
      • Transparency 
        • Healthcare professional payment transparency 
      Young girl in doctor's office
      ESG
    • News 
      • Stories 
      • News archive 
      • Novartis UK press office 
      colleagues in discussion
      News
    • Careers 
      • Career search 
      • Personal growth 
      • Early talent 
      • How we work 
      • Well-being 
      • Career programmes 
      • Awards and recognition 
      Business person with a whiteboard behind them in a modern office
      Careers
    • Contact 
    Home
    Home
Global Search Navigation
  • All
  • Site Pages
  • Media Releases
  • Stories
Sort by
Hide Filters
Showing 233 results
  • External funding (UK): Grants and Healthcare Funding — 2026 cycle

  • Media Release / Feb 16, 2026

    Novartis Pluvicto (lutetium (177Lu) vipivotide tetraxetan)▼ receives MHRA authorisation for new indication for eligible patients with PSMA‑positive metastatic castration‑resistant prostate cancer

    New indication authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) expands access to lutetium177 vipivotide tetraxetan in the UK for eligible mCRPC patients earlier in the…
  • The Clatterbridge Cancer Centre NHS Foundation Trust (CCC), 65 Pembroke Place, Liverpool L7 8YA

  • NHS Lothian, Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG

  • University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital, Eastern Road, Brighton, East Sussex, BN2 5BE

  • Willows Health Primary Care Network

  • Barts Health NHS Trust, (“Barts" or “CW Partner”) The Royal Hospital, Whitechapel Rd, London E1 1BB

  • The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ

  • Newcastle Upon Tyne Hospitals NHS Foundation Trust

  • Bristol Heart Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Trust Headquarters, Marlborough Street, Bristol, BS1 3NU. Interventional Cardiology Fellow, Associate Prof Cardiology.

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 24
  • › Next page

Related News & Media

Bold partner video screenshot
Novartis UK launches new bold partner for progress film

Novartis UK

Navigate Novartis
  • Patients and caregivers
  • ESG
  • News
  • Careers
Media Center
  • News archive
  • Stories
Our Portfolio
  • Novartis clinical pipeline
  • Novartis product information
Other Novartis Websites
  • Healthcare Professional portal
  • Novartis global
  • Advanced accelerator applications
  • Novartis biome
  • Novartis clinical trials
Footer Bottom
© 2026 Novartis Pharmaceuticals UK Ltd
  • Privacy policy
  • Terms of use
  • Contact
  • Web accessibility
  • Modern slavery statement
  • Cookie settings
Novartis Site Directory
This site is intended for an audience in the UK